Trutect’s full USDA approval sharpens parvo treatment options

CURRENT BRIEF VERSION: Elanco’s canine parvovirus monoclonal antibody has moved from conditional licensure to full USDA approval, giving veterinarians a fully licensed targeted biologic for one of small-animal practice’s most consequential infectious diseases. The product, now branded Trutect, was first conditionally licensed in May 2023, then gained an expanded passive-immunity indication for exposed puppies in June 2025, before receiving full USDA approval in December 2025. USDA product records list the biologic as anivovetmab for canine parvovirus, distributed by Elanco US Inc. (elanco.com)

Why it matters: For veterinary professionals, this is more than a branding or regulatory update. Parvo care has historically depended on aggressive supportive treatment, isolation capacity, staffing, and pet parent finances. The disease targets rapidly dividing cells, especially in the intestinal lining and bone marrow, which helps explain the severe vomiting, diarrhea, dehydration, leukopenia, and sepsis risk that make untreated infection so often fatal—particularly in vulnerable puppies, even in shelter settings where non-GP clinicians may end up managing cases. Elanco says real-world data from the first year of use found 93% survival in treated puppies and an average 1.87-day reduction in hospitalization, while a shelter-based ISCAID 2024 abstract reported significantly shorter hospitalization and faster clearance to negative SNAP testing when the monoclonal antibody was added to standard of care, even though survival was similar to standard care in that retrospective cohort. Experimental data published in 2024 also found early administration prevented mortality in all treated dogs versus 57% mortality in controls, and did not appear to interfere with adaptive immunity. Vaccination remains the foundation of prevention, but maternal antibodies can complicate early puppy vaccine response, which is part of why exposed-puppy passive-immunity use is clinically notable. (elanco.com)

What to watch: Watch for broader protocol adoption in GP, ER, and shelter medicine, plus more independent field data on case selection, timing of administration, cost-benefit, and use of the passive-immunity indication in exposed puppies. (elanco.com)